Serina Therapeutics, Inc. 8-K Filing
Ticker: SER · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Serina Therapeutics, Inc. (ticker: SER) to the SEC on Nov 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate).
How long is this filing?
Serina Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 466 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-11-03 06:03:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
Filing Documents
- ser-20251103.htm (8-K) — 23KB
- ex991_serina-regulatoryupd.htm (EX-99.1) — 14KB
- 0001708599-25-000126.txt ( ) — 160KB
- ser-20251103.xsd (EX-101.SCH) — 2KB
- ser-20251103_lab.xml (EX-101.LAB) — 23KB
- ser-20251103_pre.xml (EX-101.PRE) — 13KB
- ser-20251103_htm.xml (XML) — 3KB
01 Other Items
Item 8.01 Other Items On November 3, 2025, Serina Therapeutics, Inc. (the "Company") issued a press release providing a regulatory update on the Company's SER-252 Program, announcing that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company's Investigational New Drug (IND) application for SER-252, Serina's lead development program for advanced Parkinson's disease. A copy of the press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release , dat ed Nove mber 3, 2025, on Regulatory Update on SER-252 Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: November 3, 2025 By: /s/ Steve Ledger Chief Executive Officer